Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
Maria Frank-Kamenetsky(Alnylam Pharmaceuticals (United States)), Kevin Fitzgerald(Epsilon Systems (United States)), Robert Dorkin(Alnylam Pharmaceuticals (United States)), Jay D. Horton(Center for Human Genetics), Ingo Röhl(Roche Pharma AG (Germany)), Aldo Grefhorst(Amsterdam Neuroscience), Tracy Zimmermann(Alnylam Pharmaceuticals (United States)), Timothy Racie(Alnylam Pharmaceuticals (United States)), Antonin de Fougerolles(Alnylam Pharmaceuticals (United States)), Róbert Langer(Massachusetts Institute of Technology), Daniel G. Anderson(Boston Children's Hospital), K. N. Jayaprakash(Alnylam Pharmaceuticals (United States)), Muthusamy Jayaraman(Forma Therapeutics (United States)), David Butler(University at Albany, State University of New York), Yupeng Fan(Jilin University), Norma N. Anderson, Jürgen Soutschek(Regulus Therapeutics (United States)), Martin A. Maier(Alnylam Pharmaceuticals (United States)), Akin Akinc(Alnylam Pharmaceuticals (United States)), Philipp Hadwiger(Roche Pharma AG (Germany)), Muthiah Manoharan(Alnylam Pharmaceuticals (United States)), Lubomir V. Nechev(Alnylam Pharmaceuticals (United States)), Kallanthottathil G. Rajeev(Alnylam Pharmaceuticals (United States)), Gang Wang(Alnylam Pharmaceuticals (United States)), Timothy Read(Alnylam Pharmaceuticals (United States)), Matthias John, Pamela Tan(Roche Pharma AG (Germany)), Hans-Peter Vornlocher(Roche Pharma AG (Germany)), Victor Koteliansky(Centre National de la Recherche Scientifique), Jamie Wong(Alnylam Pharmaceuticals (United States)), Birgit Bramlage(Roche Pharma AG (Germany)), Klaus Charissé(Alnylam Pharmaceuticals (United States)), Christina Gamba‐Vitalo(Alnylam Pharmaceuticals (United States))
Cited by 641
Related Papers
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
|Journal of Clinical Investigation|2002|4k
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2017|3.8k
Transdermal drug delivery
|Nature Biotechnology|2008|3.4k
Physical and mechanical properties of PLA, and their functions in widespread applications — A comprehensive review
|Advanced Drug Delivery Reviews|2016|3.2k
Rational design of cationic lipids for siRNA delivery
|Nature Biotechnology|2010|1.8k